Keiji Wakabayashi Selected Research

7- chloro- 3- imino- 5- methyl- 2- azabicyclo(4.1.0)heptane

8/2008	Increased expression of inducible nitric oxide synthase (iNOS) in N-nitrosobis(2-oxopropyl)amine-induced hamster pancreatic carcinogenesis and prevention of cancer development by ONO-1714, an iNOS inhibitor.
8/2007	A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male Apc(Min/+) mice.
3/2006	Suppressive effect of an inducible nitric oxide inhibitor, ONO-1714, on AOM-induced rat colon carcinogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keiji Wakabayashi Research Topics

Disease

59	Carcinogenesis 11/2021 - 01/2002
58	Neoplasms (Cancer) 02/2022 - 01/2000
22	Colonic Neoplasms (Colon Cancer) 08/2017 - 01/2002
18	Adenocarcinoma 11/2020 - 04/2003
18	Intestinal Polyps 01/2019 - 09/2002
16	Colorectal Neoplasms (Colorectal Cancer) 03/2022 - 03/2006
15	Polyps 01/2021 - 09/2002
11	Inflammation (Inflammations) 05/2017 - 01/2000
10	Adenoma (Adenomas) 04/2018 - 06/2004
9	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2021 - 07/2003
9	Aberrant Crypt Foci 08/2017 - 01/2002
9	Hyperlipidemias (Hyperlipidemia) 02/2011 - 09/2003
8	Carcinoma (Carcinomatosis) 01/2021 - 01/2003
8	Body Weight (Weight, Body) 01/2014 - 06/2005
6	Pancreatic Neoplasms (Pancreatic Cancer) 05/2012 - 08/2007
4	Asthma (Bronchial Asthma) 01/2020 - 08/2018
4	Obesity 01/2016 - 08/2011
4	Gastritis 09/2013 - 02/2002
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2009 - 03/2006
3	Colitis 08/2007 - 01/2006
2	Stomach Neoplasms (Stomach Cancer) 02/2022 - 01/2012
2	Allergic Rhinitis 01/2020 - 01/2020
2	Hypertriglyceridemia 01/2016 - 04/2008
2	Breast Neoplasms (Breast Cancer) 01/2016 - 01/2002
2	Ulcer 02/2013 - 06/2011
2	Infections 01/2012 - 02/2003
2	Lung Neoplasms (Lung Cancer) 09/2009 - 02/2008

Drug/Important Bio-Agent (IBA)

16	AzoxymethaneIBA 08/2017 - 01/2002
12	Messenger RNA (mRNA)IBA 05/2017 - 01/2002
11	CarcinogensIBA 02/2020 - 01/2002
11	ProstaglandinsIBA 03/2008 - 01/2000
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2002
10	LipidsIBA 11/2011 - 03/2003
9	Triglycerides (Triacylglycerol)IBA 01/2012 - 09/2003
8	DNA AdductsIBA 01/2021 - 01/2003
8	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2017 - 01/2002
8	Drinking WaterIBA 01/2014 - 10/2003
8	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 02/2011 - 03/2002
7	colibactinIBA 03/2022 - 01/2019
7	Dextrans (Dextran)FDA Link 01/2014 - 01/2005
7	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2014 - 01/2005
7	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 03/2008 - 01/2000
7	beta CateninIBA 10/2007 - 06/2004
7	Prostaglandins EIBA 03/2007 - 01/2002
6	nitrosobis(2-oxopropyl)amine (NBOP)IBA 05/2012 - 04/2003
6	PPAR gammaIBA 01/2012 - 09/2003
6	Pioglitazone (Actos)FDA Link 01/2012 - 09/2003
6	EnzymesIBA 03/2008 - 01/2000
6	nimesulide (Aulin)IBA 03/2006 - 01/2002
6	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2006 - 01/2002
5	MutagensIBA 01/2022 - 04/2004
5	AminesIBA 01/2021 - 10/2007
5	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 02/2020 - 01/2002
5	AdipokinesIBA 01/2012 - 04/2008
5	LigandsIBA 01/2012 - 09/2003
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2012 - 09/2003
4	Pharmaceutical PreparationsIBA 11/2021 - 05/2015
4	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 02/2013
4	QuinoxalinesIBA 02/2020 - 02/2008
4	Biological ProductsIBA 02/2020 - 04/2004
4	EndotoxinsIBA 01/2020 - 08/2018
4	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 11/2004
4	PPAR alphaIBA 10/2007 - 09/2003
3	2-toluidine (o-toluidine)IBA 12/2020 - 01/2020
3	benzocycloheptapyridineIBA 02/2020 - 01/2005
3	LeptinIBA 01/2016 - 08/2011
3	Indomethacin (Indometacin)FDA LinkGeneric 11/2012 - 04/2004
3	Urethane (Ethyl Carbamate)IBA 11/2012 - 02/2008
3	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 12/2009 - 02/2005
3	7- chloro- 3- imino- 5- methyl- 2- azabicyclo(4.1.0)heptaneIBA 08/2008 - 03/2006
3	Protein Isoforms (Isoforms)IBA 03/2008 - 01/2000
3	Codon (Codons)IBA 02/2008 - 06/2004
3	Dinoprostone (PGE2)FDA Link 03/2007 - 05/2003
3	ONO 8711IBA 03/2007 - 07/2003
3	mofezolacIBA 10/2006 - 09/2002
3	Cyclooxygenase 1IBA 10/2006 - 09/2002
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2006 - 10/2003
3	Bromodeoxyuridine (BrdU)IBA 05/2005 - 09/2002
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2003 - 01/2002
2	PolyketidesIBA 01/2022 - 01/2020
2	Peptides (Polypeptides)IBA 01/2022 - 01/2020
2	AcetyltransferasesIBA 01/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 03/2006
2	Mesalamine (Mesalazine)FDA LinkGeneric 01/2021 - 01/2019
2	PowdersIBA 05/2020 - 06/2011
2	aniline (aniline hydrobromide)IBA 02/2020 - 03/2002
2	CateninsIBA 02/2020 - 01/2014
2	Particulate MatterIBA 01/2020 - 01/2020
2	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2017 - 02/2008
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 08/2017 - 05/2017
2	Interleukin-6 (Interleukin 6)IBA 05/2017 - 02/2016
2	Insulin (Novolin)FDA Link 01/2016 - 01/2012
2	CytokinesIBA 01/2016 - 06/2011
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2016 - 01/2000
2	AcidsIBA 05/2012 - 09/2008
2	Plasminogen Activators (Plasminogen Activator)IBA 06/2011 - 04/2008

Therapy/Procedure

9	Chemoprevention 12/2021 - 07/2003
3	Colectomy 01/2021 - 01/2016
2	Intraperitoneal Injections 11/2012 - 06/2011
2	Injections 06/2011 - 05/2003